TC BioPharm’s mission is to develop and commercialise innovative cell-based products to treat disease, improving patient health and Quality of Life.

TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell®, in renal cell carcinoma, non-small cell lung cancer and melanoma patients. We have a growing team based in our Glasgow and Edinburgh offices, alongside a wide range of scientific advisors, and partner organisations.